B
BioIntellisense
Continuous health monitoring and clinical intelligence company with medical-grade wearable devices and Data-as-a-Service
About BioIntellisense
BioIntelliSense is a medical technology startup that specializes in remote patient monitoring. The company offers a wearable device, the BioButton, which provides continuous, medical-grade monitoring of a patient's vital signs. This device is designed to be comfortable, discreet, and easy to use, making it an attractive option for patients who require ongoing monitoring but prefer to stay at home. The BioButton collects data that can be analyzed to detect early signs of health issues, enabling proactive medical intervention.
BioIntelliSense primarily serves hospitals, health systems, provider organizations, and payors in the U.S. and select global markets. The company's business model revolves around selling its wearable devices and providing data analytics services. By offering a cost-effective solution for continuous monitoring, BioIntelliSense can help healthcare providers improve patient care while reducing costs associated with hospital stays and emergency interventions.
The company has been recognized for its innovative approach, winning the MedTech Breakthrough Award in 2023 for Best Overall Medical Device Company. It has also established strategic partnerships with other healthcare organizations, such as Ardent Health Services, to expand its reach and impact.
The company is led by Dr. Mault, a seasoned executive with over 35 years of experience in health IT and medical device industry. He has a strong track record of innovation, with over 80 issued and pending patents to his name.
Source: Dealroom company dataAt a glance
- Founded
- 2018
- Headquarters
- Golden, United States
- Sector
- Health Tech & Medtech
- Power Law
- Colt$25–100M revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
- FIFresenius Medical Care Balboa II
Jonathan Weiner
CU Healthcare Innovation Fund
7wire Ventures
Chimera
Triple Tree Capital Partners
UCHealth- JMJames Murren
- RPRoyal Philips
Series B and later7 investors entered at this stage
- RPRoyal Philips
- JMJames Murren
- TPTriple Tree Capital Partners
- CHChimera
- 7V7wire Ventures
- UCUCHealth
- CFCU Healthcare Innovation Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about BioIntellisense on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioIntellisense on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.